GLP-1 drugsHumans10,702 participants12 monthsCohort study

Real-world treatment patterns and cost per patient achieving treatment targets among tirzepatide and semaglutide initiators in US patients with type 2 diabetes

Journal of Managed Care & Specialty Pharmacy

The paper

Meredith M. Hoog, Carlos R. Vallarino, Juan M. Maldonado,

Michael Grabner, Chia‐Chen Teng, Kendra A. Terrell,

Emma L. Richard

Eli Lilly (United States) · Carelon Research

Journal of Managed Care & Specialty Pharmacy · 30 Sep 2026

doi.org/10.18553/jmcp.2026.32.10.1173 PubMed 42808550

SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
GLP-1 agonists plus SGLT2 inhibitors lower kidney events in CKD
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk
Clinical Pharmacology and Therapeutics · 4 Oct 2026